Table 2.
Factors associated with RFS and OS significantly found by multivariate analyses in our cohort
| Factors | RFS | OS | ||
|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | |
| ALB: ≥ 35 vs < 35 g/L | - | 0.457 (0.249–0.839) | 0.011 | |
| Tumour size: > 5 vs ≤ 5 cm | 1.997 (1.408–2.832) | <0.001 | 1.933 (1.313–2.844) | 0.001 |
| Encapsulation: complete vs incomplete or absence | 0.684 (0.490–0.954) | 0.025 | 0.662 (0.472–0.930) | 0.017 |
| Satellite nodules: yes vs no | - | - | ||
| PVTT: yes vs no | 1.565 (1.006–2.436) | 0.047 | - | |
| Edmonson grade: III+IV vs I+II | - | - | ||
| TNM: II+III+IV vs I | - | - | ||
| BCLC: B+C vs A | 1.704 (1.182–2.456) | 0.004 | 2.414 (1.690–3.447) | <0.001 |
| FBP1 expression: high vs low | 0.576 (0.424–0.784) | < 0.001 | 0.582 (0.418–0.809) | 0.001 |
ALB albumin, FBP1 fructose-1,6-bisphosphatase 1, BCLC stage Barcelona Clinic Liver Cancer stage, TNM stage tumour-node-metastasis stage, PVTT portal vein tumour thrombosis